Wockhardt Limited · NSE:WOCKPHARMA
Wockhardt — Investor Presentation (February 2024)
29 slides from Wockhardt's investor presentation, Feb 26, 2024
Slide 1: Stock exchange filing cover letter
WOCK/SEC/SE/2023-24/072 26th February, 2024 BSE Limited National Stock Exchange of India Limited Corporate Relations Department Listing Department P J Towers, Exchange Plaza Dalal Street Bandra Kurla Complex, Bandra (E), Mumbai - 400 001 Mumbai - 400 051 Scrip Code: 532300 NSE Symbol – WOCKPHARMA De
Slide 2: Investor presentation 2024
Investor presentation 2024 1
Slide 3: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation") contain selected information about the activities of statements as a result of a number of risks, uncertainties and assumptions. Although the Group believes that such forward Wockhardt Limited ("Company") and its subsidiar
Slide 4: Snapshot of Wockhardt
Snapshot of Wockhardt Net sales Revenues 12 manufacturing facilities across world INR 2,129 Cr. (9M FY24) EBITDA 2 R&D centres one each in India, UK INR 173 Cr. Infrastructure (9M FY24) Net Debt: Equity Ratio ~ 315 scientists with 55 PhD’s; Drug 0.27x* Discovery team ~ 125 associates (as on Septembe
Slide 5: Global footprint
Global footprint Global operations Capability across different segments ► Branded ► Antibiotics Drug Discovery ► OTC ► Biotechnology ► Hospitals ► Pharma Generics ► Solids ► Liquids ► Injectables ► Nasal sprays ► Biotechnology ► Complex technologies Direct operations Through Partners United Kingdom
Slide 6: Financial Highlights
Financial Highlights Net Sales Revenues INR Cr. EBITDA INR Cr. 307 3,239 328 2,840 489 2,693 7% growth 130 80% growth 26 2,129 1,983 5 173 24 5 143 19 2,710 2,750 2,667 71 96 2,124 98 17 168 1,959 124 79 -27 -21 FY21 FY22 FY23 9M FY23 9M FY24 FY21 FY22 FY23 9M FY23 9M FY24 FY Figures Excl. Vaccine F
Slide 7: Reduction in External Term Loans
Reduction in External Term Loans Reduction in external term loan* (INR Cr.) 2,054 1,262 825 555 438 Mar-20 Mar-21 Mar-22 Mar-23 Sep-23 *Excluding promoter debt & preference capital 6
Slide 8: Net Debt : Equity @ 0.27
Net Debt : Equity @ 0.27* Total Borrowings* Reduction by > INR 600 Cr. Total Equity INR Cr. Total Borrowings* INR Cr. 4,202 1,568 3,759 3,662 3,432 975 882 933 FY21 FY22 FY23 6M FY24 FY21 FY22 FY23 6M FY24 Cash & cash equivalents and other Bank balances INR Cr. Net Debt-Equity Ratio * 406 0.42 292 0
Slide 9: Additional Short-term and Mid-term growth drivers
Additional Short-term and Mid-term growth drivers 3 years growth drivers 5 years growth drivers Diabetes Biosimilars for India + Novel drug discovery – WCK 5222, 1 Emerging markets – Human Insulin & 1 Nafithromycin, WCK 6777 Glargine Novel drug discovery - WCK 5222, Diabetes Biosimilars for India +
Slide 10: New Chemical Entity (Antibiotics)
New Chemical Entity (Antibiotics) 9
Slide 11: Anti-microbial resistance could cause 10 million deaths by 2050
Anti-microbial resistance (AMR) could cause 10 million deaths by 2050 ‘Tackling Drug-Resistant infections globally’ chaired by JIM O’NEILL- Former Minister, UK Govt. & Former Chairman Goldman Sachs’ Deaths attributable to antimicrobial resistance every year compared to other major causes of death A
Slide 12: Wockhardt's Novel Antibiotics
Wockhardt’s Novel Antibiotics ~25 Focused commitment to Novel Antibiotics research leading to end-to-end Discovery & Development capabilities years 6 Programs granted QIDP* status by US FDA denoting unmet needs; faster trials, quicker approvals by US FDA * Qualified Infectious Disease Product (QIDP)
Slide 13: Novel Antibiotics pipeline encompassing all the Resistant Organisms
Novel Antibiotics pipeline encompassing all the Resistant Organisms Gram Negative Portfolio Gram Positive Portfolio Emrok / WCK 5222 WCK 4282 WCK 6777 Nafithromycin Emrok O Meropenem Phase I Launched in India; Global Phase III Phase III Phase III completion Status resistant pathogen In collaboration
Slide 14: WCK 5222 Development Status
WCK 5222 Development Status (Brand name: ZaynichTM *) WCK 5222 (Cephalosporin + β-lactam enhancer) – Destination therapy for XDR Gram Negative Acinetobacter & Pseudomonas Pre-clinical Phase I Phase II1 Global Phase III Regulatory Global Completed (on-going) filings Launch ► Phase I studies completed
Slide 15: WCK 5222: Compassionate use results (1/2)
WCK 5222: Compassionate use results in 15 patients (incl. 2 paediatric) (1/2) DRUG RESISTANCE WCK 5222 Patients with Life threatening Pathogen and Drug Efficacy Treat- Drug 1 Drug 2 Drug 3 Drug 4 Safety #. Failed treatment infections Resistance ment Outcomes Duration Complicated intra-abdominal Pseu
Slide 16: WCK 5222: Compassionate use results (2/2)
WCK 5222: Compassionate use results in 15 patients (incl. 2 paediatric) (2/2) DRUG RESISTANCE WCK 5222 Patients with Life threatening Pathogen and Drug Efficacy Treat- Drug 1 Drug 2 Drug 3 Drug 4 Safety # Failed treatment infections Resistance ment Outcomes Duration Liver Transplant, HTN, Hypothroid
Slide 17: Pathogens and indications treated with WCK 5222 in compassionate setting
Pathogens inflicting infections and associated indications while treating 15 patients with WCK 5222 in compassionate setting Complete clinical as well as microbiological cure attained in all patients Indication wise split for patients treated 15 Patients Treatment under compassionate use Pathogen tr
Slide 18: WCK 5222 differentiation
Strictly confidential. Not for further circulation WCK 5222 differentiation Activity against resistant infection Best comparable Pipeline Drugs Best available Approved Drugs WCK Organism/ Resistance Mech. Product 1 Product 2 Product 3 Product 4 Product 5 Product 6 Product 7 Product 8 Product 9 52221
Slide 19: Top 6 Super bugs inflicting global mortality in 2019
Top 6 Super bugs inflicting global mortality in 2019 - more than 3.5 Millions deaths Number of deaths associated with Anti-Microbial Resistance* 829,000 748,000 642,000 596,000 423,000 334,000 Acinetobacter Escherichia Coli Klebsiella Pseudomonas Staphylococcus Pneumococcus WCK 5222 is designed to a
Slide 20: Nafithromycin: Broad spectrum novel lactone ketolide
Nafithromycin (Brandname: MiqnafTM *): Broad spectrum novel lactone ketolide for Community Acquired Bacterial Pneumonia (CABP) and Upper Respiratory tract infections(RTI) Increasing resistance and incomplete coverage for current treatment options: 1 • Azithromycin resistance in S. Pneumonia of ~65%
Slide 21: EMROK & EMROK O: Multi-spectrum anti-MRSA Drug
EMROK & EMROK O: Multi-spectrum anti-MRSA Drug Emrok / Emrok O®: Launched in India and filed in select Emerging markets New Age Antibiotic : Benzoquinolizine sub-class Multi-spectrum activity: Safe Oral and IV antibiotic with coverage of MDR Gram Positive pathogens including MRSA, Gram Negative, Ana
Slide 22: Biotechnology
> 60 S fe) c ca a) ® ed 2 cn Saving Lives years ,
Slide 23: Strategic pillars of Diabetes Biosimilars
Strategic pillars of Diabetes Biosimilars Focus on Diabetes Injectable portfolio Vertically integrated Research and Development Human Insulin, Insulin Glargine commercialized Yeast, mammalian and bacterial platform Drug substance manufacturing Robust Pipeline of Insulin Analogs and 4 facilities GLP1
Slide 24: Competitive advantage by providing end-to-end solutions in Diabetes Biosimilars
Competitive advantage by providing end-to-end solutions in Diabetes Biosimilars Integrated capabilities R&D Manufacturing Regulatory Devices Focus on Insulin Pilot to large scale Registrations in 40+ Customised precision analogues, GLP1 capabilities for API & countries patented delivery agonists for
Slide 25: Development status of Insulin analogues and GLP-1 agonist
Development status of Insulin analogues and GLP-1 agonist Aspart R Aspart 30/70 Lispro R Lispro 25/75 Liraglutide Process development ✓ ✓ ✓ ✓ ✓ Process Scale Up ✓ ✓ ✓* ✓* Ongoing Drug substance validation ✓ ✓ ✓* ✓* batches Drug product validation ✓ batches Planned PK/PD study ✓ Planned Planned Plann
Slide 26: Diabetes Biosimilars for Emerging markets - Competitive scenario
Diabetes Biosimilars for Emerging markets - Competitive scenario 6-7 Barriers to entry- 1 Limited competition development time, players dedicated manufacturing Under registration in 7 2 Registered in emerging markets > 40 markets countries Manufacturing infrastructure ready API + Low cost manufactur
Slide 27: Vaccine: Supply & Collaboration agreement with Serum at UK Facility
Vaccine: Supply & Collaboration agreement with Serum at UK Facility • Profit sharing of 51:49 with Serum Life Sciences Limited in favor of Wockhardt • 15 years arrangement • Reserved capacity of 150 million doses per annum 26
Slide 28: Abbreviation
Abbreviation ABSSSI: Acute bacterial skin and skin structure infections; MBL : Metallo-β-lactamases AmpC : AmpC beta-lactamases MDR: Multidrug resistance AMR: Antimicrobial resistance MENA: Middle East and North Africa API: Active Pharmaceutical Ingredient MRSA : Methicillin-resistant Staphylococcus
Slide 29: Thank You
88 | LiFE AvockHakor \¥iEks Thank You